Zhenyu Yue, PhD
- PROFESSOR | Neurology
- PROFESSOR | Neuroscience
Research Topics:
Apoptosis/Cell Death, Autophagy, Axonal Growth and Degeneration, Human Genetics and Genetic Disorders, Knockout Mice, Lysosomes/endosome, Molecular Biology, Neuro-degeneration/protection, Parkinson's Disease, Protein Degradation, Protein Kinases, Protein Trafficking & Sorting, Synapses
Molecular, Cellular, Behavioral Biology and Translational Research in Neurodegeneration
Our long-term goal is to understand the molecular and cellular mechanisms of neurodegeneration that causes human neurological disorders such as Parkinson’s, Huntington’s and Alzheimer’s diseases. Our mission is to translate our knowledge from basic research to the development of molecular diagnostics and therapeutics for neurological disorders. Our primary research interests encompass molecular and cellular pathways for autophagy-lysosome degradation, protein quality control (aggregate clearance), synaptic vesicle trafficking, neuroinflammation, and protein/lipid kinase signaling in neuropathogenesis.
Other Web Sites
Yue Laboratory
Multi-Disciplinary Training Areas
Neuroscience [NEU], Pharmacology and Therapeutics Discovery [PTD]
Research Areas:
- Autophagy-lysosome pathway as neuroprotection mechanism in the maintenance of axon and dendrite homeostasis and the clearance of protein aggregates, including polyQ expansion proteins (such as Huntingtin), tau and alpha-synuclein.
- The regulation of autophagy and endocytosis in neurons and neurodegeneration by PI3K-III lipid kinase complex proteins, including the modulators/adaptors: Beclin 1, Atg14L, URRAG, Rubicon and NRBF2; development of small compounds as modulators for PI3K-III activity and neuronal autophagy.
- Protein/lipid kinase and phosphatase in regulating synaptic vesicle trafficking and dysfunction in neurotransmission underlying Parkinson’s disease.
- The contribution of peripheral immune system and CNS glial cells to the neuroinflammation pathways underlying neurodegeneration mechanism in Parkinson’s disease and other human disorders.
- The molecular, cellular, and structural dissection of LRRK2 kinase in familial Parkinson’s disease; kinase inhibitor development as therapeutics to treat Parkinson’s disease.
- Genetic animal model development for human movement disorders and neurodegenerative diseases.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Yue during 2018 and/or 2019. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Royalty Payments:
- Genentech, Inc.; Pfizer Inc.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.